Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracoronary abciximab and aspiration thrombectomy in anterior STEMI undergoing primary PCI
NL-OMON35318Phase 3Active, not recruiting
- Sponsor
- Atrium Medical Corporation
- Start
- Jan 2010
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of abciximab in myocardial infarction (MI) (4 arms), sponsored by Atrium Medical Corporation. Primary endpoint: Infarct size at 30 days by cardiac MRI. Started Jan 2010; status: active, not recruiting.
02
Drugs
abciximab
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NL-OMON35318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35318.